Vascular endothelial growth factor (VEGF) has also been identified as a key target for anti-angiogenic therapy, and its inhibitors bevacizumab, sorafenib, and sunitinib are also used for breast cancer therapy11,12. This evidence concerns the gene VEGFA and breast carcinoma.